Fairmount Funds Management LLC

WEST CONSHOHOCKEN, PA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.59B2026 Q3
Positions12
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.97.5%

Fairmount Funds Management LLC reported 12 positions worth $1.59B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: ORKA (19.4%). Biggest move: new buy KRSA ($291.3M).

10 / 12 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 ORKAOruka Therapeutics$308.6M19.35%3,705,262——+19.1%
▸ 2 KRSAKorsana Biosciences$291.3M18.27%9,103,729———
▸ 3 DNTHDianthus Therapeutics$223.4M14.01%2,537,191——+1.7%
▸ 4 DMRADamora Therapeutics$185.4M11.63%8,713,000——+1.5%
▸ 5 COGTCogent Biosciences$176.2M11.05%5,503,418——-10.8%
▸ 6 VRDNViridian Therapeutics$104.8M6.57%5,090,928——+49.9%
▸ 7 ELVNEnliven Therapeutics$85.1M5.33%1,855,644——+3.9%
▸ 8 JBIOJade Biosciences$64.0M4.01%4,553,494———
▸ 9 ZBIOZenas BioPharma$64.0M4.01%2,371,358———
▸ 10 CBIOCrescent Biopharma$52.5M3.30%3,601,316——-3.0%

Pro Feature

The remaining 2 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Fairmount Funds Management LLC hold as of Q3 2026?

Fairmount Funds Management LLC reported 12 positions worth $1.59B in its Q3 2026 13F filing. Largest positions: ORKA (19.4%), KRSA (18.3%), DNTH (14.0%), DMRA (11.6%) and COGT (11.1%).

What did Fairmount Funds Management LLC buy in Q3 2026?

New positions: KRSA and DMRA. Added to: CBIO and ZBIO.

What did Fairmount Funds Management LLC sell in Q3 2026?

Sold out entirely: DAMORA THERAPEUTICS INC and APOGEE THERAPEUTICS INC.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.